AOD-9604
Also known as: Anti-Obesity Drug 9604, hGH Fragment 176-191, Tyr-hGH Frag 176-191
AOD-9604 is not FDA-approved for human therapeutic use. Clinical trials for obesity did not advance to Phase 3. For research and informational purposes only.
Overview
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. It was developed to replicate the fat-metabolizing activity of hGH without the growth-promoting, insulin-desensitizing, or mitogenic effects of full-length hGH. Research has focused on its ability to stimulate lipolysis and inhibit lipogenesis through a non-GHR-dependent mechanism.
Research Summary
Animal studies consistently demonstrate that AOD-9604 reduces body fat in obese rodents without affecting blood glucose or IGF-1 levels — a significant distinction from hGH. It appears to act directly on fat cells via beta-adrenergic pathways. Phase 2 human clinical trials for obesity were conducted but did not meet primary endpoints for the oral formulation; injectable forms were not advanced to Phase 3. AOD-9604 received GRAS (Generally Recognized As Safe) status in the US for food use, though this does not confer therapeutic approval.
Dosing Range
low
250mcg
moderate
500mcg
high
1000mcg
Units: mcg · Frequency: Once daily, on an empty stomach
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Reconstitute with 1–2 mL bacteriostatic water per vial. Refrigerate at 2–8°C. Use within 30 days of reconstitution. Protect from light.Step-by-step reconstitution guide →
Supplies you'll need
Affiliate links — Research Stack may earn a small commission at no extra cost to you.
Reported Side Effects
- Injection site redness or irritation
- Mild flushing (transient)
- Headache (rare)
- Considered low side-effect profile compared to full hGH
Research Papers
3 peer-reviewed sourcesCommunity Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Community experiences are mixed — some report modest fat loss improvements when stacked with CJC-1295/ipamorelin; others see minimal standalone effect. Most users note the absence of significant side effects.
View original threadDiscussions on AOD-9604's role in cutting protocols. Community consensus is that it works best as part of a broader GH-axis stack rather than as a standalone compound.
View original threadWant to calculate your dose? Use the dosing calculator →